May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
What does the future hold for the US pharma industry?
Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.
Pharma companies are increasingly looking for ways to provide “beyond the pill” services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment…
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.
Exploring the opportunities for pharma in the ASEAN region and factors to consider when conducting healthcare market research.
Understanding the opportunities for biosimilars and the threats to innovator biologics
The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers…
Utilising the benefits of mobile technology
Presenting a window on the world of your customer
